The global denture industry is witnessing two key developments: growing recognition of removable dentures' efficacy in periodontal disease restoration and potential trade disruptions from a new US ITC Section 337 investigation into dental burs.
Recent clinical data highlights removable dentures as a preferred non-invasive solution for edentulous patients with periodontal issues. A 2025 study showed a 92.5% total effective rate in periodontal repair with removable dentures, outperforming fixed dentures' 75% efficacy. These dentures enhance chewing efficiency to 74.78% and reduce periodontal probing depth to 1.38mm, while their removable design facilitates thorough cleaning and minimizes plaque buildup. With over 190 million adults globally relying on dentures in 2025, this clinical evidence is driving market demand, projected to reach $4078.44 million by 2035.
Meanwhile, the US International Trade Commission launched a Section 337 investigation (337-TA-1479) on January 14, 2026, targeting certain dental burs and kits. Initiated following complaints of patent and trademark infringement, the probe names respondents from Pakistan, the UK, Canada, and other countries. Dental burs are critical for denture fabrication, and the investigation may delay supply chains or impose exclusion orders, impacting global denture manufacturers' production workflows.
Industry experts note the dual trend underscores the need for both clinical innovation and trade compliance, as manufacturers balance advancing removable denture technologies with navigating regulatory risks.